Design, synthesis and biological evaluation of caffeoyl benzanilides as dual inhibitors of HIV integrase and CCR512. Issue 10 (17th August 2016)

• Record Type: Journal Article
• Authors: Sun, Xuefeng; Fan, Ningning; Xu, Weisi; Sun, Yixing; Xie, Xin; Guo, Ying; Ma, Liying; Liu, Junyi; Wang, Xiaowei
• Is Part Of: MedChemComm. Volume 7:Issue 10(2016:Oct.)
• Page Start: 2028
• Page End: 2032
• Publication Date: 2016-08-17
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c6md00311g
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : Novel series of caffeoyl benzanilides have been synthesized and evaluated as dual inhibitors of HIV-1 CCR5/IN. Compound9a exhibited the possibility of being a dual inhibitor of HIV-1. Abstract : Novel series of caffeoyl benzanilide compounds as dual inhibitors of HIV-1 CCR5/IN were designed and synthesized. The biological results indicated that the acetylated compounds with double bonds were reduced, especially compound9a, which showed potential activity against HIV-1 CCR5 tropic viruses with an EC50 value of 4.85 μM, as well as binding affinity with IN ( K D 2.4 μM). Molecular modeling studies also suggested the possible binding mode of9a with CCR5 and IN. These results indicated that9a has the possibility of being a dual inhibitor of HIV-1.